An Introduction About SNORD115-30 (G100033804)

Target Name: SNORD115-30

NCBI ID: G100033804

SNORD115-30

Other Name(s): small nucleolar RNA, C/D box 115-30 | Small nucleolar RNA, C/D box 115-30 | HBII-52-30

An Introduction About SNORD115-30

The discovery of novel disease drug targets and biomarkers holds immense potential for revolutionizing medical treatments and improving patient outcomes. In recent years, researchers have explored the role of small nucleolar RNAs (snoRNAs) such as SNORD115-30 as potential candidates in this context. This article aims to delve into the significance of SNORD115-30 as a potential disease drug target or biomarker, exploring its function, expression patterns, and implications in various diseases.

What is SNORD115-30?

SNORD115-30 is a member of the SNORD115 family - group of snoRNAs localized to the chromosomal region 15q11-q13 in humans. These snoRNAs are transcribed from non-protein coding regions of the genome and play critical roles in the maturation and modification of ribosomal RNA (rRNA). SNORD115-30 specifically guides the 2'-O-ribose methylation of specific nucleotides in the 18S rRNA of the small ribosomal subunit.

The Role of SNORD115-30 in Normal Cellular Function

In normal cellular functioning, SNORD115-30 is involved in maintaining proper ribosome formation and function. By guiding the methylation of certain nucleotides in rRNA, it helps regulate the accuracy and efficiency of protein synthesis, a fundamental process in all living organisms. Disruptions in SNORD115-30 expression or function can potentially impact ribosome biogenesis, leading to impaired protein synthesis and subsequent cellular dysfunction.

Expression Patterns of SNORD115-30

SNORD115-30 exhibits tissue-specific expression patterns, primarily found in the brain, particularly within neurons. It is particularly abundant in certain regions associated with cognitive functions, such as the cerebral cortex and hippocampus. Interestingly, SNORD115-30 also exhibits imprinted expression, meaning it is only expressed from the allele inherited from a specific parent (most often the paternal allele). This imprinted expression pattern suggests a potential role of SNORD115-30 in brain development and function.

SNORD115-30 as a Disease Drug Target

The aberrant expression or dysfunction of SNORD115-30 has been implicated in various neurodevelopmental and neuropsychiatric disorders, raising the possibility of targeting this snoRNA for therapeutic interventions. One notable example is Angelman syndrome, a rare genetic disorder characterized by severe developmental delays, intellectual disabilities, and neurological impairments. It has been observed that SNORD115-30 expression is significantly reduced in individuals with Angelman syndrome, potentially contributing to the manifestation of the disorder. Restoring SNORD115-30 expression or function might hold therapeutic promise in ameliorating some symptoms of Angelman syndrome.

Moreover, SNORD115-30 has also been associated with other neurodevelopmental disorders, such as Prader-Willi syndrome and autism spectrum disorders (ASD). In both cases, disrupted SNORD115-30 expression has been reported. Targeting SNORD115-30 could potentially offer novel therapeutic strategies to alleviate the symptoms and improve the quality of life for individuals affected by these conditions.

SNORD115-30 as a Potential Biomarker

Besides its potential as a therapeutic target, SNORD115-30 may also serve as a valuable biomarker for certain diseases. Biomarkers play a crucial role in disease diagnosis, prognosis, and monitoring treatment efficacy. Recent studies have shown the potential of snoRNAs, including SNORD115-30, as non-invasive biomarkers for various diseases due to their presence and stability in body fluids such as blood, urine, and cerebrospinal fluid.

For example, studies have indicated that altered expression levels of SNORD115-30 are associated with neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. These findings suggest the possibility of utilizing SNORD115-30 expression levels as a biomarker to aid early diagnosis or track disease progression in these conditions, potentially leading to more timely and effective interventions.

Conclusion

In conclusion, the snoRNA SNORD115-30 represents a fascinating molecule with significant potential as both a disease drug target and a biomarker. Its involvement in critical cellular processes, coupled with its tissue-specific expression patterns, make it an attractive candidate for exploring therapeutic interventions in neurodevelopmental disorders. Additionally, its presence and stability in body fluids open up exciting possibilities for its utilization as a non-invasive biomarker in neurodegenerative diseases. Further research and exploration of SNORD115-30's function and implications are needed to fully realize its therapeutic and diagnostic potential.

Protein Name: Small Nucleolar RNA, C/D Box 115-30

The "SNORD115-30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD115-30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets